106 related articles for article (PubMed ID: 9086130)
1. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons.
Davey RT; Chaitt DG; Piscitelli SC; Wells M; Kovacs JA; Walker RE; Falloon J; Polis MA; Metcalf JA; Masur H; Fyfe G; Lane HC
J Infect Dis; 1997 Apr; 175(4):781-9. PubMed ID: 9086130
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection.
Davey RT; Chaitt DG; Albert JM; Piscitelli SC; Kovacs JA; Walker RE; Falloon J; Polis MA; Metcalf JA; Masur H; Dewar R; Baseler M; Fyfe G; Giedlin MA; Lane HC
J Infect Dis; 1999 Apr; 179(4):849-58. PubMed ID: 10068580
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.
Tambussi G; Ghezzi S; Nozza S; Vallanti G; Magenta L; Guffanti M; Brambilla A; Vicenzi E; Carrera P; Racca S; Soldini L; Gianotti N; Murone M; Veglia F; Poli G; Lazzarin A
J Infect Dis; 2001 May; 183(10):1476-84. PubMed ID: 11319683
[TBL] [Abstract][Full Text] [Related]
4. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Losso MH; Belloso WH; Emery S; Benetucci JA; Cahn PE; Lasala MC; Lopardo G; Salomon H; Saracco M; Nelson E; Law MG; Davey RT; Allende MC; Lane HC
J Infect Dis; 2000 May; 181(5):1614-21. PubMed ID: 10823761
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
Eton O; Rosenblum MG; Legha SS; Zhang W; Jo East M; Bedikian A; Papadopoulos N; Buzaid A; Benjamin RS
Cancer; 2002 Jul; 95(1):127-34. PubMed ID: 12115326
[TBL] [Abstract][Full Text] [Related]
6. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.
Lalezari JP; Beal JA; Ruane PJ; Cohen CJ; Jacobson EL; Sundin D; Leong WP; Raffanti SP; Wheeler DA; Anderson RD; Keiser P; Schrader SR; Goodgame JC; Steinhart CR; Murphy RL; Wolin MJ; Smith KA
HIV Clin Trials; 2000; 1(3):1-15. PubMed ID: 11590500
[TBL] [Abstract][Full Text] [Related]
7. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
[TBL] [Abstract][Full Text] [Related]
8. Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients.
Herzmann C; Cuthbertson Z; Fosdick L; Fisher M; Nelson M; Perry N; Law M; Wand H; Janossy G; Johnson MA; Youle M
J Antimicrob Chemother; 2008 Sep; 62(3):583-6. PubMed ID: 18587135
[TBL] [Abstract][Full Text] [Related]
9. CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies.
Arduino RC; Nannini EC; Rodriguez-Barradas M; Schrader S; Losso M; Ruxrungtham K; Allende MC; Emery S; Fosdick L; Neaton J; Tavel JA; Davey RT; Lane HC; ;
Clin Infect Dis; 2004 Jul; 39(1):115-22. PubMed ID: 15206062
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide production in HIV-1 infected patients receiving intermittent cycles of interleukin-2 and antiretrovirals.
Torre D; Speranza F; Ghezzi S; Nozza S; Tambussi G; Soldini L; Dorigatti F; Lazzarin A; Tambini R; Poli G
HIV Clin Trials; 2004; 5(3):146-51. PubMed ID: 15248139
[TBL] [Abstract][Full Text] [Related]
11. Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042.
Bartlett JA; Berend C; Petroni GR; Ottinger J; Tyler DL; Pettinelli C; Weinhold KJ
J Infect Dis; 1998 Oct; 178(4):1170-3. PubMed ID: 9806053
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2.
Fortis C; Soldini L; Ghezzi S; Colombo S; Tambussi G; Vicenzi E; Gianotti N; Nozza S; Veglia F; Murone M; Lazzarin A; Poli G
AIDS Res Hum Retroviruses; 2002 May; 18(7):491-9. PubMed ID: 12015902
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of intermittent subcutaneous IL-2 administration in pediatric patients with moderate immune suppression: results of Pediatric AIDS Clinical Trials Study 402.
Pahwa S; Muresan P; Sleasman J; Fenton T; Moye J; Deveikis A; Wara D; Van Dyke R;
J Allergy Clin Immunol; 2007 Jun; 119(6):1538-41. PubMed ID: 17418382
[No Abstract] [Full Text] [Related]
15. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 CD4+ T cells.
de Boer AW; Markowitz N; Lane HC; Saravolatz LD; Koletar SL; Donabedian H; Yoshizawa C; Duliege AM; Fyfe G; Mitsuyasu RT
Clin Immunol; 2003 Mar; 106(3):188-96. PubMed ID: 12706405
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with Arnó A; Ruiz L; Juan M; Jou A; Balagué M; Zayat MK; Marfil S; Martínez-Picado J; Martínez MA; Romeu J; Pujol-Borrell R; Lane C; Clotet B
J Infect Dis; 1999 Jul; 180(1):56-60. PubMed ID: 10353861
[TBL] [Abstract][Full Text] [Related]
18. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.
Kovacs JA; Vogel S; Albert JM; Falloon J; Davey RT; Walker RE; Polis MA; Spooner K; Metcalf JA; Baseler M; Fyfe G; Lane HC
N Engl J Med; 1996 Oct; 335(18):1350-6. PubMed ID: 8857018
[TBL] [Abstract][Full Text] [Related]
19. Phase IB study on prevention of surgery-induced immunodeficiency with preoperative administration of low-dose subcutaneous interleukin-2 in gastric cancer patients.
Cerea K; Romano F; Bravo AF; Motta V; Uggeri F; Brivio F; Fumagalli LA; Uggeri F
J Surg Oncol; 2001 Sep; 78(1):32-7. PubMed ID: 11519066
[TBL] [Abstract][Full Text] [Related]
20. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group.
Carr A; Emery S; Lloyd A; Hoy J; Garsia R; French M; Stewart G; Fyfe G; Cooper DA
J Infect Dis; 1998 Oct; 178(4):992-9. PubMed ID: 9806026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
